Heterotopic Transcatheter Tricuspid Valve Replacement in a Patient With Carcinoid Heart Disease

Lukas Stolz; Philipp M Doldi; Ludwig T Weckbach; Robert H G Schwinger; Thomas J Stocker; Steffen Massberg; Michael Näbauer; Jörg Hausleiter

doi:10.1016/j.jaccas.2022.10.011

Heterotopic Transcatheter Tricuspid Valve Replacement in a Patient With Carcinoid Heart Disease

JACC Case Rep. 2022 Nov 16;4(23):101679. doi: 10.1016/j.jaccas.2022.10.011. eCollection 2022 Dec 7.

Authors

Lukas Stolz¹, Philipp M Doldi¹, Ludwig T Weckbach^{1

2}, Robert H G Schwinger³, Thomas J Stocker^{1

2}, Steffen Massberg^{1

2}, Michael Näbauer^{1

2}, Jörg Hausleiter^{1

2}

Affiliations

¹ Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Munich, Germany.
² German Center for Cardiovascular Research, Partner Site Munich Heart Alliance, Munich, Germany.
³ Medizinische Klinik II, Klinikum Weiden, Kliniken Nordoberpfalz AG, Weiden, Germany.

Abstract

Neuroendocrine tumors can lead to carcinoid heart disease with subsequent development of severe tricuspid regurgitation due to thickening and restriction of the tricuspid leaflets. We present a patient who underwent successful heterotopic transcatheter tricuspid valve replacement for torrential tricuspid regurgitation due to carcinoid heart disease. (Level of Difficulty: Intermediate.).

Keywords: CT, computed tomography; MRI, magnetic resonance imaging; NYHA, New York Heart Association; TR, tricuspid regurgitation; TV, tricuspid valve; carcinoid heart disease; right-side heart failure; tricuspid regurgitation; tricuspid valve replacement.

Publication types

Case Reports